Impedimed Ltd (IPD)
Australian Securities Exchange · Australia · prices in AUD · close of 21 Oct 2026
Key indicators
| Last close | AUD 0.004 |
|---|---|
| 52-week range | 0.003 – 0.051 |
| Return, 1 month / 3 months | −20.0% / +0.0% |
| Return, 1 year / 3 years | −90.5% / −96.8% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 159.6% |
| Worst drawdown (1 year) | -92.0% |
| Average daily value traded | 0.03M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
ImpediMed is an Australian medical device company that makes bioimpedance spectroscopy equipment for clinicians. Its devices measure fluid status and body composition non-invasively, and are used in the assessment and monitoring of lymphoedema, particularly in patients treated for breast cancer. The company supplies hospitals, clinics and healthcare professionals, and its products are used in cancer care and rehabilitation settings. ImpediMed is based in Australia and serves customers in several countries.
Impedimed Ltd trades under the code IPD on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Impedimed Ltd (IPD) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.004 on 21 October 2026.
Its price-based Market X-Ray is 15 out of 100 (a weak price profile), ranking 1,716 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 90.5% and over the last three months it rose 0.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 2 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -63.7% | ||
| From 52-week high | -92.0% | ||
| Momentum | 21 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.0% | ||
| 6-month return | -73.3% | ||
| 12-month return, skipping the last month | -88.1% | ||
| Stability (higher is calmer) | 3 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 159.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -92.0% | ||
| Liquidity | 46 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M AUD | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −42.9% |
|---|---|
| 1 month | −20.0% |
| 3 months | +0.0% |
| 6 months | −73.3% |
| 1 year | −90.5% |
| 3 years | −96.8% |
| 5 years | −97.6% |
Signals
| 50-day / 200-day average | 0.005 / 0.011 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.001 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.